Asking Price: $5,000,000
Location: Plymouth Meeting, PA (Montgomery County – Life Sciences Corridor)
Establishment: 2018 (8 Years in Operation)
Transaction Type: Asset Sale (Lease & Lease-to-Own Options Available)
Investment Thesis
This is a rare opportunity to acquire a fully equipped pharmaceutical and cosmetic formulation laboratory in the heart of the Pennsylvania life sciences corridor. Established in 2018, this facility offers a "plug-and-play" solution for a biotech startup, a Contract Research Organization (CRO) looking to expand, or a cosmetic manufacturer seeking high-end R&D capabilities.
With a proven track record in ANDA product development and FDA registration, the laboratory is outfitted with over $5M worth of specialized equipment and instrumentation. By acquiring this turnkey asset package, a buyer eliminates the 12–18 month lead time typically required for facility build-out, equipment sourcing, and validation.
High-Value Asset Inventory
1. Analytical Laboratory (QC & Stability)
A comprehensive suite of instrumentation for API and finished dosage testing:
Chromatography & Mass Spec: HPLC systems, Headspace GC-MS, and Ion Chromatography (IC).
General Analytical: Auto Titrators, Karl Fischer (KF), TGA, FT-IR, and Laser PSD.
Testing Systems: Auto-Dissolution systems and specialized Inhalation Testing equipment.
2. Oral Solid Dosage (OSD) & Pilot Plant
Full capabilities for tablets, capsules, and pellets:
Compression: Auto Bilayer Press and an instrumented single-station press.
Processing: Coating machine with exchangeable pans, Roller Compactor, and High-Shear Granulators.
Blending & Milling: Comil and PK blenders.
Specialized Systems: Glatt Fluid-Bed System with Multi-Particulate (Pelleting) DDS capabilities—a premier unit in the US market.
3. Specialized Manufacturing
Inhalation Lines: Complete systems for mixing, filling, assembling, and testing inhalation products.
Semi-Auto Testing: Integrated tablet testing systems for immediate QC feedback during production.
Core Capabilities
Formulation Development: Expertise in preclinical/clinical manufacturing, bioequivalent studies, and complex P4 ANDA strategies.
Analytical Services: Method development, forced-degradation studies, and full FDA registration stability testing.
Regulatory Success: Proven history of navigating complex FDA requirements and supporting patent litigation for ANDA products.
Growth & Expansion Potential
Strategic Location: Located in Plymouth Meeting, PA, offering access to an elite pool of pharmaceutical talent and proximity to major industry hubs.
Immediate Market Entry: The facility is ready for immediate operation, making it ideal for a company needing to meet tight clinical or regulatory deadlines.
Service Expansion: Ample infrastructure to scale into cosmetic "clean beauty" formulations or complex generic drug development.
Support & Financing
Flexible Terms: The seller is offering Lease and Lease-to-Own options to accommodate a variety of capital structures.
Expert Transition: To ensure continued success, the seller will provide introductions to a network of industrial experts for operational and regulatory guidance.
Reason for Sale: Owner is divesting to focus on other business interests.
